Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

BACKGROUND: In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we repor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6837258/
https://ncbi.nlm.nih.gov/pubmed/31362993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-215764
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados